Cilostazol, a phosphodiesterase (PDE) III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications. It has been used over the past 25 years for improving intermittent claudication in patients with peripheral artery disease (PAD). Cilostazol also has demonstrated efficacy in patients undergoing percutaneous revascularization procedures, both for PAD and coronary artery disease (CAD). In addition to its antithrombotic and vasodilating actions, cilostazol also inhibits vascular smooth muscle cell proliferation via PDE III inhibition, thus mitigating restenosis. Accumulated evidence has shown that cilostazol, due to its "pleiotropic" effects, is a useful, albeit underutilized agent, for both CAD and PAD. It is also potentially useful after ischemic stroke and is an alternative in those who are allergic or intolerant to classical antithrombotic agents (e.g., aspirin or clopidogrel). These issues are herein reviewed together with the pharmacology and pharmacodynamics of cilostazol. Large studies and meta-analyses are presented and evaluated. Current guidelines are also discussed and the spectrum of cilostazol's actions and therapeutic applications are illustrated. This article is protected by copyright. All rights reserved.
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications.